The Rise of the Naked Injectable:
A Clinical and Consumer Perspective on Xeomin vs. Botox in Aesthetic Medicine

In an ever-evolving aesthetic landscape, injectables have become one of the most sought-after cosmetic interventions globally. Among these, botulinum toxin type A continues to dominate for its ability to temporarily reduce dynamic wrinkles, rejuvenate the skin, and prevent signs of aging. As the demand for minimally invasive procedures increases, the distinction between neuromodulator products such as Botox and Xeomin has become more relevant than ever. Taliah Wylie, a certified cosmetic injector renowned for her precision and natural aesthetic outcomes, brings a fresh, research-driven voice to this critical discussion. Her clinical practice is rooted in transparency, ethics, and a minimalistic approach — values that align with the growing consumer interest in cleaner formulations.

Taliah Wylie is a certified cosmetic injector and the founder of Tula Tu Aesthetics, a boutique injectables practice based in Houston, Texas. With an extensive background in both aesthetic medicine and brand strategy, Taliah has distinguished herself through her focus on natural-looking results, client education, and ethical practice. Originally trained in South Africa, she later pursued advanced certification and training in the United States. Her expertise lies in facial anatomy, precision neurotoxin injection, and personalized anti-aging strategies. Taliah is a vocal advocate for patient empowerment and is recognized for her role in demystifying aesthetic procedures for the modern consumer.

Botulinum toxin type A is the cornerstone of nonsurgical facial rejuvenation, with Botox (onabotulinumtoxinA) long held as the gold standard since its FDA approval in 2002. However, in recent years, Xeomin (incobotulinumtoxinA) has emerged as a cleaner, potentially safer alternative due to its unique formulation — free from accessory proteins. This study explores the clinical distinctions between the two products, their safety and efficacy profiles, and the broader implications for consumers and injectors alike.

While both Botox and Xeomin are botulinum toxin type A, the primary differentiator lies in their composition. Botox contains complexing proteins in addition to the core neurotoxin, while Xeomin is considered a “naked” injectable — it undergoes a proprietary purification process that strips away these accessory proteins.

Key Clinical Insight:

• According to Jankovic et al. (2013), the absence of complexing proteins in Xeomin may reduce the likelihood of antibody formation, which can render treatments less effective over time.
• A head-to-head trial published in Aesthetic Surgery Journal (Sattler et al., 2012) found no significant difference in efficacy between the two, though Xeomin had a faster onset in some cases.

Clinical trials and anecdotal injector reports suggest both Xeomin and Botox provide comparable efficacy in the treatment of glabellar lines, crow’s feet, and forehead wrinkles.

Duration Comparison:

• Botox typically maintains results for 3–4 months.
• Xeomin’s results are comparable, though some practitioners report variability in onset and wear-off times depending on patient metabolism and muscle strength.

A study by Moers-Carpi et al. (2011) found Xeomin to be non-inferior to Botox in clinical results, with patient satisfaction remaining high across both groups.

The potential development of neutralizing antibodies with long-term, repeated Botox use is a growing concern. While rare, resistance can develop, especially in younger patients receiving prophylactic injections over many years.

Xeomin Advantage:

• The removal of accessory proteins is believed to reduce antigenicity, thus decreasing the likelihood of immunoresistance (Naumann & Jankovic, 2004).
• For patients showing reduced response to Botox, transitioning to Xeomin may restore treatment efficacy.

Consumers are increasingly seeking clean-label beauty and health products, driven by a desire to reduce exposure to unnecessary additives. Xeomin’s marketing as a “naked injectable” aligns perfectly with this shift.

Survey Data:

• A 2022 report by the American Society for Aesthetic Plastic Surgery found a 20% increase in Xeomin usage among first-time neurotoxin users.
• Social media trends and influencer marketing have also contributed to Xeomin’s positioning as the modern alternative to Botox.

However, Botox still holds unmatched brand recognition and patient trust, making it a powerful contender despite newer options.

Injectors must consider several variables when selecting a neurotoxin for their clients:

• Patient History: Those who have developed tolerance to Botox may benefit from Xeomin.
• Lifestyle and Philosophy: Clients drawn to clean living and minimalism often prefer Xeomin.
• Clinical Goals: Some injectors find Botox easier to dose due to longer-standing familiarity and deeper clinical data.

Injector Tip: Transitioning a client from Botox to Xeomin should include a clear explanation of expected differences, including potential changes in onset and muscle response.

The debate between Botox and Xeomin is less about superiority and more about suitability. Both products offer excellent clinical outcomes when used correctly. The growing shift toward Xeomin is not simply a trend, but a reflection of broader consumer values around purity, safety, and personalization in aesthetic medicine.

Injectors who embrace both products, tailoring choices to individual needs, will not only future-proof their practices but also deepen client trust and satisfaction.

1. Jankovic J, et al. (2013). “IncobotulinumtoxinA (Xeomin) for cervical dystonia and blepharospasm.” Expert Review of Neurotherapeutics, 13(8), 1039–1053.
2. Sattler G, et al. (2012). “Double-blind, randomized, placebo-controlled study of the efficacy and safety of incobotulinumtoxinA in the treatment of glabellar frown lines.” Aesthetic Surgery Journal, 32(6), 672–683.
3. Moers-Carpi M, et al. (2011). “Double-blind, randomized, parallel-group study of the safety and efficacy of incobotulinumtoxinA and onabotulinumtoxinA in the treatment of glabellar frown lines.” Journal of the American Academy of Dermatology, 64(4), 682–690.
4. Naumann M, Jankovic J. (2004). “Safety of botulinum toxin type A: a systematic review and meta-analysis.” Current Medical Research and Opinion, 20(7), 981–990.
5. American Society for Aesthetic Plastic Surgery. (2022). Cosmetic Surgery National Data Bank Statistics.